+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 357 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the combination of CGT9486 and sunitinib compared to sunitinib alone in patients with locally advanced, unresectable, or metastatic Gastrointestinal Stromal Tumors GIST. This Phase 3, open-label international trial involves multiple parts, including dose confirmation, drug interaction assessments, and efficacy comparisons. The study also includes substudies focusing on drug-drug interaction potential and first-line treatment in patients with specific genetic mutations KIT exon 9. Approximately 482 patients will participate across these parts.

Age: 18Years +All GendersPhase 3
126 locations
U

Actively Recruiting

Carcinoma of unknown primary origin CUP is a group of cancers where metastatic disease is present but the original tumor cannot be found despite extensive tests. This condition limits treatment options since therapies often target known primary tumors. Researchers are evaluating whether a new imaging test called 18FF-fluoro fibroblast activation protein inhibitor F-FAPI PET-CT can detect the primary tumor in patients diagnosed with CUP after standard diagnostic scans including FDG PET-CT. This multi-center, prospective clinical study involves 50 adult patients with CUP to better understand the usefulness of this new scan method. Each participant will undergo a single 18FF-FAPI PET-CT scan at one of the six study centers. Images from this scan will be centrally reviewed and shared with the treating doctor, who may recommend further tests or treatments based on the findings. After six months, results from the F-FAPI PET-CT will be compared with clinical, radiological, and pathological follow-up data. A multidisciplinary panel will then review all information to decide how valuable the 18FF-FAPI PET-CT is for identifying the primary tumor in CUP patients. Participants will be involved in one main scanning visit and followed for six months through routine clinical assessments. The study team will monitor detection of the primary tumor using the new scan as the main outcome, and also assess the tests accuracy measures like sensitivity and specificity. Participation requires being able to undergo the scan and complete follow-up, with the entire process lasting about two years for outcome measurement. This study is sponsored by Erasmus Medical Center.

Age: 18Years - 99YearsAll GendersPhase Not Applicable
6 locations
P

Actively Recruiting

Researchers are evaluating the diagnostic performance of 68GaBED003 in detecting several types of cancer, including colorectal cancer, gastric cancer, pancreatic ductal adenocarcinoma, invasive lobular breast cancer, and epithelial ovarian cancer. This multi-centre, open-label, single-arm Phase 2 study aims to understand how well this PET imaging agent works in identifying these cancers. Participants receive an injection of 68GaBED003 followed by positron emission tomography PET combined with computed tomography CT imaging during a dedicated visit. The study monitors the diagnostic accuracy of the imaging, assesses tumor uptake of the agent, and evaluates safety and tolerability up to 42 days after injection. The first six participants also help determine optimal imaging timing and dosing. During the study, participants undergo screening, imaging, and safety follow-up, including pregnancy testing for women of childbearing potential. Researchers collect imaging data and monitor for any adverse effects up to 48 hours after injection and continue follow-up assessments for up to 42 days. Overall participation lasts from screening through safety follow-up and post-imaging observation.

Age: 18Years - 79YearsAll GendersPhase 2
6 locations
E

Actively Recruiting

Researchers are investigating new treatment options for people with locally advanced or metastatic colorectal cancer mCRC that cannot be removed by surgery and has a specific gene mutation called KRAS G12C. The study aims to evaluate the safety and tolerance of combining calderasib, cetuximab, and mFOLFOX6 chemotherapy compared to the standard treatment of mFOLFOX6 with or without bevacizumab. This research is a phase 3 clinical trial focused on improving outcomes for this specific patient group. Participants will be assigned to one of two groups. One group receives calderasib tablets orally, cetuximab every two weeks, and mFOLFOX6 chemotherapy including oxaliplatin, leucovorin or levofolinate calcium, and 5-fluorouracil every two weeks. The other group receives mFOLFOX6 chemotherapy with or without bevacizumab or a bevacizumab biosimilar, also administered every two weeks. Treatment continues until doctors decide to stop based on specific criteria. During the study, participants will be closely monitored for side effects and treatment tolerability, with evaluations lasting up to about 44 months in the first part and up to 5 years in the second part. Researchers will collect data on progression-free survival, response rates, overall survival, and quality of life using various questionnaires. Safety assessments and tracking of any adverse events will be conducted regularly throughout the study.

Age: 18Years +All GendersPhase 3
245 locations
E

Actively Recruiting

Researchers are investigating new treatments for metastatic castration-resistant prostate cancer mCRPC. This study evaluates the medicine ifinatamab deruxtecan I-DXd or MK-2400 compared to chemotherapy to see if it helps people live longer overall and without cancer progression. The trial is sponsored by Merck Sharp & Dohme LLC and focuses on men with advanced prostate cancer who have tried other therapies. Participants are randomly assigned to one of two groups. One group receives I-DXd at 12 mg per kg every three weeks through intravenous infusion, along with premedication to prevent nausea and vomiting. The other group receives docetaxel chemotherapy at 75 mgm every three weeks plus daily oral prednisone. Treatments continue until the cancer worsens, side effects are unacceptable, or treatment stops for other reasons. During the study, participants will have regular assessments to monitor overall survival and how long they live without cancer progression, up to about 36 months. Researchers will also track additional outcomes like time to subsequent therapies, response rates, pain progression, and side effects. Safety and treatment tolerability will be closely monitored throughout the trial, which may last up to six years for some participants.

Age: 18Years +MALEPhase 3
303 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of ifinatamab deruxtecan I-DXd, alone or combined with other treatments, in people with metastatic castration-resistant prostate cancer mCRPC. This study aims to understand how well participants tolerate the treatment, find a safe dose level for combination therapies, and monitor prostate-specific antigen PSA levels during treatment. The study is part of a larger master screening protocol and includes participants with advanced prostate cancer. Participants may receive one of several treatment plans docetaxel chemotherapy every three weeks for up to 10 cycles I-DXd alone every three weeks until side effects, disease progression, death, or withdrawal I-DXd combined with opevesostat after dose escalation until stopping criteria are met or I-DXd combined with an androgen receptor pathway inhibitor abiraterone or enzalutamide under similar conditions. Before each I-DXd dose, participants take medications to prevent nausea and vomiting. During the study, participants will have regular assessments including monitoring for treatment side effects, PSA response, and disease progression. Researchers will track dose-limiting toxicities, adverse events, and reasons for stopping treatment over periods ranging from about three weeks to over four years. Secondary measures include overall survival, radiographic progression-free survival, and time to pain progression. Participation may last several years, with ongoing safety and effectiveness evaluations carried out throughout this time.

Age: 18Years +All GendersPhase 1Phase 2
82 locations
O

Actively Recruiting

Researchers are studying MK-8294, a targeted therapy designed to treat advanced or metastatic solid tumors such as head and neck squamous cell carcinoma, cervical squamous cell carcinoma, esophageal squamous cell carcinoma, triple-negative breast cancer, certain hormone receptor-positive breast cancers, endometrial, and bladder cancers. This Phase 1, open-label study aims to evaluate the safety, tolerance, and highest dose of MK-8294 that patients can handle. The study is sponsored by Merck Sharp & Dohme LLC and focuses on treatment for participants who have failed standard therapies or have no other options. Participants will receive MK-8294 alone through intravenous infusion at escalating doses starting from 30 micrograms up to 70 milligrams, including possible intermediate doses. The drug is administered on Days 1, 8, and 15 of each 21-day cycle, with no maximum number of cycles specified. Treatment continues until discontinuation criteria are met. Optional imaging with a CD8 PET tracer may be performed as part of the study. During the study, participants will be closely monitored for adverse events and treatment tolerance up to two years. Evaluations include blood tests measuring MK-8294 drug levels and immune responses, as well as safety assessments for dose-limiting toxicities. The study tracks objective tumor responses along with the presence of antidrug antibodies. Participants will have regular visits for treatment and assessments throughout their participation, which may last several cycles depending on individual response and tolerability.

Age: 18Years +All GendersPhase 1
8 locations
P

Actively Recruiting

Researchers are investigating the effects of an experimental drug called BNT323 also known as DB-1303 compared with standard chemotherapy in women with recurrent endometrial cancer that expresses the HER2 protein. This Phase III study includes two groups based on HER2 levels one group with lower HER2 expression 1 or 2 who have previously received immune checkpoint inhibitors, and another with higher HER2 expression 3. The study aims to evaluate how well these treatments control the cancer and their safety profiles. Participants in Cohort 1 will be randomly assigned to receive either BNT323 or a chemotherapy drug chosen by their doctor, such as doxorubicin or paclitaxel or docetaxel if paclitaxel is unsuitable. Cohort 2 participants will receive BNT323 alone. Treatments are given through intravenous infusions and continue until the cancer progresses, unacceptable side effects occur, or consent is withdrawn. The study includes screening, treatment lasting about six months, and long-term follow-up for up to 53 months to monitor survival and other outcomes. During the trial, participants will undergo various assessments including imaging scans to measure tumor size, evaluations of side effects, blood tests to study drug behavior and immune responses, and quality of life questionnaires. Safety follow-up occurs shortly after treatment ends, followed by extended monitoring for treatment effectiveness and survival. Participants are closely observed throughout to understand how well BNT323 works compared to chemotherapy and its impact on health and wellbeing.

Age: 18Years +FEMALEPhase 3
206 locations
E

Actively Recruiting

Researchers are evaluating the effects of enicepatide, a dual GLP-1GIP receptor agonist, for weight management in adults who have obesity or overweight with at least one related health condition, but do not have Type 2 diabetes. The study is a phase III, randomized, double-blind, placebo-controlled trial designed to assess the safety and efficacy of multiple doses of enicepatide compared with placebo. Participants will be randomly assigned to receive one of several dosing regimens of enicepatide or a placebo, administered once weekly using an integrated drug-device combination product. The treatment period lasts for 72 weeks, during which participants will self-administer the injections or receive assistance if needed. The placebo is volume-matched to the active drug to maintain blinding. Throughout the study, participants will have their body weight and other health measures evaluated regularly. Assessments include changes in waist circumference, blood glucose, insulin, cholesterol levels, blood pressure, and health-related quality of life. Safety is monitored by tracking adverse events and questionnaires related to mental health. The primary outcome is the percentage change in body weight from baseline to week 72, and the total participation duration covers this entire period.

Age: 18Years +All GendersPhase 3
209 locations
E

Actively Recruiting

Researchers are investigating new treatments to prevent non-small cell lung cancer NSCLC from returning after surgery in people with high-risk, localized Stage I NSCLC. This Phase 3 randomized clinical trial compares adjuvant intismeran autogene V940 alone or combined with subcutaneous pembrolizumab and berahyaluronidase alfa against placebo in participants who have had their cancer completely removed. The goal is to improve disease-free survival in these patients. Participants are assigned to one of three groups one receives intismeran 1 mg by intramuscular injection plus pembrolizumab with berahyaluronidase alfa by subcutaneous injection another group receives intismeran alone by intramuscular injection and the third group receives a placebo injection. Treatments are given as part of the study, with dosing schedules and combinations designed to evaluate their effects on cancer recurrence. During the study, participants will be closely monitored through regular assessments including imaging scans and laboratory tests to track disease status and side effects. Researchers will measure outcomes such as disease-free survival, distant metastasis-free survival, overall survival, and quality of life using standardized questionnaires. Safety will also be monitored throughout the study, which may last up to several years for some participants.

Age: 18Years +All GendersPhase 3
124 locations

1-10 of 357

1